Terns Pharmaceuticals Inc (TERN)

NASDAQ
Currency in USD
2.970
-0.180(-5.71%)
Real-time Data·
TERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9353.140
52 wk Range
1.86511.400
Key Statistics
Edit
Prev. Close
3.15
Open
3.08
Day's Range
2.935-3.14
52 wk Range
1.865-11.4
Volume
314.38K
Average Vol. (3m)
1.07M
1-Year Change
-49.6%
Book Value / Share
3.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TERN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.688
Upside
+495.54%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Terns Pharmaceuticals Inc Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc SWOT Analysis


Financial Outlook
Learn about Terns' strong cash position of $373 million, funding operations into 2028, with an average analyst price target of $20
Market Potential
Analysts project a 27% to 62% stock price increase based on TERN-601's competitive efficacy in the lucrative obesity treatment market
Clinical Breakthroughs
Delve into TERN-701's impressive Phase 1 results for CML, showcasing efficacy and safety advantages over existing therapies
Promising Pipeline
Explore Terns Pharmaceuticals' innovative treatments for chronic liver diseases, cancer, and obesity, with lead candidates TERN-701 for CML and TERN-601 for obesity
Read full SWOT analysis

Compare TERN to Peers and Sector

Metrics to compare
TERN
Peers
Sector
Relationship
P/E Ratio
−2.9x−0.3x−0.5x
PEG Ratio
−0.210.000.00
Price / Book
0.8x0.2x2.6x
Price / LTM Sales
-1.8x3.0x
Upside (Analyst Target)
-157.7%52.7%
Fair Value Upside
Unlock9.0%7.6%Unlock

Analyst Ratings

7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.688
(+495.54% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.26 / -0.30
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

8.35
REPL
-9.14%
13.91
KROS
-1.63%
29.91
CRNX
-4.65%
9.55
STOK
-4.98%
15.30
OSCR
-7.10%

FAQ

What Is the Terns Pharmaceuticals (TERN) Stock Price Today?

The Terns Pharmaceuticals stock price today is 2.97

What Stock Exchange Does Terns Pharmaceuticals Trade On?

Terns Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Terns Pharmaceuticals?

The stock symbol for Terns Pharmaceuticals is "TERN."

What Is the Terns Pharmaceuticals Market Cap?

As of today, Terns Pharmaceuticals market cap is 258.96M.

What Is Terns Pharmaceuticals's Earnings Per Share (TTM)?

The Terns Pharmaceuticals EPS (TTM) is -1.08.

When Is the Next Terns Pharmaceuticals Earnings Date?

Terns Pharmaceuticals will release its next earnings report on Aug 11, 2025.

From a Technical Analysis Perspective, Is TERN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Terns Pharmaceuticals Stock Split?

Terns Pharmaceuticals has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.